Intersecting pathways: The role of hybrid E/M cells and circulating tumor cells in cancer metastasis and drug resistance

Basit Öğe Kaydı
dc.authorscopusidAli Zarrabi / 23483174100
dc.authorwosidAli Zarrabi / GSA-3718-2022
dc.contributor.authorHariri, Amirali
dc.contributor.authorMirian, Mina
dc.contributor.authorKhosravi, Arezoo
dc.contributor.authorZarepour, Atefeh
dc.contributor.authorIravani, Siavash
dc.contributor.authorZarrabi, Ali
dc.date.accessioned2025-04-17T13:36:33Z
dc.date.available2025-04-17T13:36:33Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Biyomedikal Mühendisliği Bölümü
dc.description.abstractCancer metastasis and therapy resistance are intricately linked with the dynamics of Epithelial-Mesenchymal Transition (EMT) and Circulating Tumor Cells (CTCs). EMT hybrid cells, characterized by a blend of epithelial and mesenchymal traits, have emerged as pivotal in metastasis and demonstrate remarkable plasticity, enabling transitions across cellular states crucial for intravasation, survival in circulation, and extravasation at distal sites. Concurrently, CTCs, which are detached from primary tumors and travel through the bloodstream, are crucial as potential biomarkers for cancer prognosis and therapeutic response. There is a significant interplay between EMT hybrid cells and CTCs, revealing a complex, bidirectional relationship that significantly influences metastatic progression and has a critical role in cancer drug resistance. This resistance is further influenced by the tumor microenvironment, with factors such as tumor-associated macrophages, cancer-associated fibroblasts, and hypoxic conditions driving EMT and contributing to therapeutic resistance. It is important to understand the molecular mechanisms of EMT, characteristics of EMT hybrid cells and CTCs, and their roles in both metastasis and drug resistance. This comprehensive understanding sheds light on the complexities of cancer metastasis and opens avenues for novel diagnostic approaches and targeted therapies and has significant advancements in combating cancer metastasis and overcoming drug resistance. © 2024 Elsevier Ltd
dc.description.sponsorshipAmirali Hariri and Mina Mirian appreciate the financial support of the Vice-presidency for Research of Isfahan University of Medical Sciences, Isfahan (Grant No. 3400877 and 1401305), Vice-presidency for Research of Isfahan University of Medical Sciences, Isfahan(3400877, 1401305)
dc.identifier.citationHariri, A., Mirian, M., Khosravi, A., Zarepour, A., Iravani, S., & Zarrabi, A. (2024). Intersecting Pathways: The Role of Hybrid E/M Cells and Circulating Tumor Cells in Cancer Metastasis and Drug Resistance. Drug Resistance Updates, 101119.
dc.identifier.doi10.1016/j.drup.2024.101119
dc.identifier.issn13687646
dc.identifier.pmid39111134
dc.identifier.scopus2-s2.0-85200320134
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://hdl.handle.net/20.500.12713/6276
dc.identifier.volume76
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorZarrabi, Ali
dc.institutionauthoridAli Zarrabi / 0000-0003-0391-1769
dc.language.isoen
dc.publisherChurchill Livingstone
dc.relation.ispartofDrug Resistance Updates
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCancer Metastasis
dc.subjectCircular Tumor Cells Drug Resistance
dc.subjectEpithelial-Mesenchymal Transition
dc.titleIntersecting pathways: The role of hybrid E/M cells and circulating tumor cells in cancer metastasis and drug resistance
dc.typeOther

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
1-s2.0-S1368764624000773-main.pdf
Boyut:
2.77 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Biyomedikal Mühendisliği Bölümü Diğer Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu